References:  
  1. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303(6):322-4.
  2. Cannom DS, Prystowsky EN. The evolution of the implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004;27(3):419-31.
  3. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91-e220.
  4. Kuschyk J, Muller-Leisse J, Duncker D, Tulumen E, Fastenrath F, Fastner C, et al. Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies. Int J Cardiol. 2021;323:100-5.
  5. Lambiase PD, Theuns DA, Murgatroyd F, Barr C, Eckardt L, Neuzil P, et al. Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. Eur Heart J. 2022;43(21):2037-50.
  6. Boveda S, Lenarczyk R, Fumagalli S, Tilz R, Goscinska-Bis K, Kempa M, et al. Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey. Europace. 2018;20(5):887-92.
  7. Lin, G., Nishimura, R. A., Connolly, H. M., Dearani, J. A., Sundt, T. M., & Hayes, D. L. (2005). Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. Journal of the American College of Cardiology45 (10), 1672-1675.
  8. Zhang, X. X., Wei, M., Xiang, R., Lu, Y. M., Zhang, L., Li, Y. D., … & Zhou, X. H. (2022). Incidence, risk factors, and prognosis of tricuspid regurgitation after cardiac implantable electronic device implantation: a systematic review and meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia36 (6), 1741-1755.
  9. Breeman, K. T. N., Peijster, A. J. L., De Bruin-Bon, H. A. C. M., Pepplinkhuizen, S., Van der Stuijt, W., De Veld, J. A., … & Knops, R. E. (2023). Worsening tricuspid regurgitation after ICD implantation is rather due to transvenous lead than natural progression. International journal of cardiology376 , 76-80.
  10. Anvardeen, K., Rao, R., Hazra, S., Hay, K., Dai, H., Stoyanov, N., … & Chan, K. L. (2019). Prevalence and significance of tricuspid regurgitation post-endocardial lead placement. JACC: Cardiovascular Imaging12 (3), 562-564.
  11. Mondésert B, Bashir J, Philippon F, Dubuc M, Amit G, Exner D, Joza J, Birnie DH, Lane C, Tsang B, Korley V, Spears D, Ling A, Djuric A, Crystal E, Hruczkowski T, Roux JF, Carroll S, Essebag V, Krahn AD, Healey JS. Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. Am Heart J. 2019 Jan;207:1-9. doi: 10.1016/j.ahj.2018.09.008. Epub 2018 Oct 9. PMID: 30399474.
  12. Nordkamp, L. R. O., Brouwer, T. F., Barr, C., Theuns, D. A., Boersma, L. V., Johansen, J. B., … & Knops, R. E. (2015). Inappropriate shocks in the subcutaneous ICD: incidence, predictors and management. International journal of cardiology195 , 126-133.
  13. Willy K, Reinke F, Rath B, Ellermann C, Wolfes J, Bogeholz N, et al. Pitfalls of the S-ICD therapy: experiences from a large tertiary centre. Clin Res Cardiol. 2021;110(6):861-7.
  14. Pothineni NVK, Cherian T, Patel N, Smietana J, Frankel DS, Deo R, et al. Subcutaneous Implantable Cardioverter-defibrillator Explantation-A Single Tertiary Center Experience. J Innov Card Rhythm Manag. 2022;13(4):4947-53.
  15. Sink, J., Peigh, G., Speakman, B., Banno, J., Sanders, D., Nso, N., … & Verma, N. (2024). Correlation between high-and low-voltage impedance measurements following subcutaneous implantable cardioverter-defibrillator implantation. Heart rhythm21 (4), 492-494.
  16. Frankel DS, Burke MC, Callans DJ, Stivland TM, Duffy E, Epstein AE. Impact of Body Mass Index on Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator. JACC Clin Electrophysiol. 2018 May;4(5):652-659. doi: 10.1016/j.jacep.2017.11.019. Epub 2018 Feb 2. PMID: 29798794.
  17. Amin, Anish K., et al. ”Factors associated with high-voltage impedance and subcutaneous implantable defibrillator ventricular fibrillation conversion success.” Circulation: Arrhythmia and Electrophysiology  12.4 (2019): e006665.
  18. Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65(16):1605-15.
  19. Knops RE, Pepplinkhuizen S, Delnoy P, Boersma LVA, Kuschyk J, El-Chami MF, et al. Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J. 2022;43(47):4872-83.
  20. Gold, M. R., Aasbo, J. D., Weiss, R., Burke, M. C., Gleva, M. J., Knight, B. P., Miller, M. A., Schuger, C. D., Carter, N., Leigh, J., Brisben, A. J., & El-Chami, M. F. (2022). Infection in patients with subcutaneous implantable cardioverter-defibrillator: Results of the S-ICD Post Approval Study. Heart rhythm19 (12), 1993-2001. https://doi.org/10.1016/j.hrthm.2022.07.031
  21. Harcombe, A. A., Newell, S. A., Ludman, P. F., Wistow, T. E., Sharples, L. D., Schofield, P. M., … & Petch, M. C. (1998). Late complications following permanent pacemaker implantation or elective unit replacement. Heart80 (3), 240-244.
  22. Klug, D., Balde, M., Pavin, D., Hidden-Lucet, F., Clementy, J., Sadoul, N., … & Kacet, S. (2007). Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation116 (12), 1349-1355.
  23. Catanchin, A., Murdock, C. J., & Athan, E. (2007). Pacemaker infections: a 10-year experience. Heart, Lung and Circulation16 (6), 434-439.
  24. Sohail, M. R. (2007). Management of infected pacemakers and implantable cardioverter-defibrillators. Internal Medicine Journal37 (7), 509-10.
  25. Gasperetti, A., Schiavone, M., Ziacchi, M. et al.  Combined Use of S-ICD and Absorbable Antibacterial Envelopes: A Proof-of-concept Study. J Interv Card Electrophysiol  (2022). https://doi.org/10.1007/s10840-022-01222-z
  26. Hoster C, Rahman A, Goyal A, Peigh G, Trohman R, Knight BP, Huang H, Krishnan K, Larsen T, Mazur A, Sharma P, Engelstein E, Verma N, Wasserlauf J. Subcutaneous implantable cardioverter-defibrillator implantation position predicts successful defibrillation in obese and non-obese patients. J Interv Card Electrophysiol. 2023 Jan 3. doi: 10.1007/s10840-022-01462-z. Epub ahead of print. PMID: 36596954.
  27. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA, 3rd, et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2012;9(10):1737-53.